Sarepta Risk and the FDA
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.
NASDAQ
Sarepta Therapeutics, Inc.
SRPT
1 article
$2.1B Market cap · 2026-08-21
NASDAQ
SRPT
1 article
$2.1B Market cap · 2026-08-21
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.